Attached files
| file | filename |
|---|---|
| EX-99.1 - PRESS RELEASE - ORAGENICS INC | d596768dex991.htm |
| EX-99.2 - INTERVIEW EXCERPT - ORAGENICS INC | d596768dex992.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934.
Date of Report: August 26, 2013
(Date of earliest event reported)
Oragenics, Inc.
(Exact name of registrant as specified in its charter)
| FL | 001-32188 | 59-3410522 | ||
| (State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification Number) |
| 4902 Eisenhower Boulevard, Suite 125 Tampa, FL |
33634 | |
| (Address of principal executive offices) | (Zip Code) |
813-286-7900
(Registrant’s telephone number, including area code)
Not Applicable
(Former Name or Former Address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| Item 8.01 | Other Events. |
On August 26, 2013, Oragenics, Inc. (“Oragenics’ or the “Company”) issued a press release announcing initial success in the second phase of its lantibiotic development project through its collaboration work with Intrexon Corporation. A copy of the Press Release is attached as Exhibit 99.1 to this Report on Form 8-K and is incorporated herein by reference.
On September 12, 2013, StreetWise Reports published an interview with Keith Markey, Ph.D., a Griffin Securities, Inc. (“Griffin”) equities analyst, which included comments about the Company. The Company has an existing advisory relationship with Griffin. Dr. Markey’s comments during the interview relating to the Company are excerpted and attached hereto as Exhibit 99.2.
| Item 9.01. | Financial Statements and Exhibits. |
| Exhibit |
Description | |
| 99.1 | Press Release dated August 26, 2013. | |
| 99.2 | Excerpt of Keith Markey’s Interview with StreetWise Reports. | |
SIGNATURES
In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized on this 12th day of September, 2013.
| ORAGENICS, INC. (Registrant) | ||
| BY: | /s/ Michael Sullivan | |
| Michael Sullivan Chief Financial Officer | ||